Study Title
A Phase 3, Randomized, Double-Blind Study of Pembrolizumab versus Placebo in Combination with Adjuvant Chemotherapy With or Without Radiotherapy for the Treatment of Newly Diagnosed High-Risk Endometrial Cancer After Surgery With Curative Intent. (GOG-3053)
Purpose
The treatment of participants with newly diagnosed, high-risk EC following surgery with curative intent.
Eligibility
Study Process
Trial Details
Investigator:
Destin Black, M.D.
IRB:
Western
IRB Number:
Trial Type:
Device
Sponsor:
Merck
Contact Information:
Gynecologic Oncology Associates
(318) 212-8727
http://www.wkgynonc.com